Advertisement
Letter to the Editor| Volume 82, P130-132, December 2020

Download started.

Ok

Cause of death and risk factors for mortality in AA amyloidosis: A French retrospective study

  • Alexandre Terré
    Affiliations
    Sorbonne University, AP-HP, Tenon hospital, Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Paris GRC -28, France
    Search for articles by this author
  • Samuel Deshayes
    Affiliations
    Normandie Univ, UNICAEN, CHU de Caen Normandie, Department of Internal Medicine, Caen 14000, France
    Search for articles by this author
  • Léa Savey
    Affiliations
    Sorbonne University, AP-HP, Tenon hospital, Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Paris GRC -28, France
    Search for articles by this author
  • Gilles Grateau
    Affiliations
    Sorbonne University, AP-HP, Tenon hospital, Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Paris GRC -28, France

    Inserm UMRS_933, et laboratoire de génétique, Trousseau hospital, AP-HP, Faculté de médecine - Sorbonne University, Paris, France
    Search for articles by this author
  • Sophie Georgin-Lavialle
    Correspondence
    Corresponding author at: Sorbonne University Assistance Publique-Hôpitaux de Paris. Centre de référence des maladies auto-inflammatoires et des amyloses inflammatoires (CEREMAIA), Department of Internal medicine, Tenon hospital, 20, rue de la Chine, Paris 75020, France.
    Affiliations
    Sorbonne University, AP-HP, Tenon hospital, Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Paris GRC -28, France

    Inserm UMRS_933, et laboratoire de génétique, Trousseau hospital, AP-HP, Faculté de médecine - Sorbonne University, Paris, France
    Search for articles by this author
Published:August 14, 2020DOI:https://doi.org/10.1016/j.ejim.2020.08.012
Cause of death and risk factors for mortality in AA amyloidosis: A French retrospective study
Previous ArticlePatterns of anticoagulation for atrial fibrillation in cancer patients referred to cardio-oncological evaluation
Next ArticleHealthy and non healthy obese patients. The truth lies in the adipose tissue

      Highlights

      • •
        AA amyloidosis epidemiology is evolving with a decrease of cases caused by inflammatory rheumatism.
      • •
        Infections are now the most frequent cause of death of patients suffering from AA amyloidosis.
      • •
        Several factors are associated with the mortality in AA amyloidosis, such as the cause of the amyloidosis, or the presence of a nephrotic syndrome.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Westermark G.T.
        • Fändrich M.
        • Westermark P.
        AA amyloidosis: pathogenesis and targeted therapy.
        Annu Rev Pathol. 2015; 10: 321-344
        View in Article
        • Lachmann H.J.
        • Goodman H.J.B.
        • Gilbertson J.A.
        • Gallimore J.R.
        • Sabin C.A.
        • Gillmore J.D.
        • et al.
        Natural history and outcome in systemic AA amyloidosis.
        N Engl J Med. 2007; 356: 2361-2371
        View in Article
        • Lane T.
        • Pinney J.H.
        • Gilbertson J.A.
        • Hutt D.F.
        • Rowczenio D.M.
        • Mahmood S.
        • et al.
        Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre.
        Amyloid. 2017; 24: 162-166
        View in Article
        • Stankovic Stojanovic K.
        • Georgin-Lavialle S.
        • Poitou C.
        • Buob D.
        • Amselem S.
        • Grateau G.
        • et al.
        AA amyloidosis is an emerging cause of nephropathy in obese patients.
        Eur J Intern Med. 2017; 39: e18-e20
        View in Article
        • Gertz M.A.
        • Comenzo R.
        • Falk R.H.
        • Fermand J.P.
        • Hazenberg B.P.
        • Hawkins P.N.
        • et al.
        Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.
        Am J Hematol. 2005; 79: 319-328
        View in Article

      6. Modern Applied Statistics with S, 4th ed [Internet]. [cited 2019 Nov 21]. Available from: http://www.stats.ox.ac.uk/pub/MASS4/.

        View in Article
        • Thomas B.
        • Matsushita K.
        • Abate K.H.
        • Al-Aly Z.
        • Ärnlöv J.
        • Asayama K.
        • et al.
        Global cardiovascular and renal outcomes of reduced GFR.
        J Am Soc Nephrol JASN. 2017; 28: 2167-2179
        View in Article
        • Papa R.
        • Lachmann H.J.
        Secondary, AA, amyloidosis.
        Rheum Dis Clin North Am. 2018; 44: 585-603
        View in Article
        • Palladini G.
        • Riva E.
        • Basset M.
        • Russo F.
        • Milani P.
        • Pasquinucci E.
        • et al.
        Prognostication of survival and progression to dialysis in AA amyloidosis.
        Amyloid. 2017; 24: 136-137
        View in Article
        • D'Hoore W.
        • Sicotte C.
        • Tilquin C.
        Risk adjustment in outcome assessment: the Charlson comorbidity index.
        Methods Inf Med. 1993; 32: 382-387
        View in Article

      Article info

      Publication history

      Published online: August 14, 2020
      Accepted: August 10, 2020
      Received: August 3, 2020

      Identification

      DOI: https://doi.org/10.1016/j.ejim.2020.08.012

      Copyright

      © 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX